Filtered By:
Condition: Thrombosis
Cancer: Brain Cancers
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 106 results found since Jan 2013.
E-164 Recurrent strokes as the initial presentation of colorectal adenocarcinoma
ConclusionCryptogenic strokes in patients with cancer are cardioembolic manifestations of cancer-mediated hypercoagulability such as NBTE, which consists of sterile, platelet-fibrin vegetations on cardiac valves. The mechanism of thromboembolism in patients with cancer is based on the interaction between tumor cells and leukocytes, which creates a thrombogenic vascular lining and induces the release of substances that activate the coagulation cascade. The diagnosis of NBTE should depend on the distribution of occluded vessels, identification of thrombus, and exclusion of other possible causes such as infective endocarditis...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Babici, D., Phillip Johansen, P., Rodriguez-Hernandez, A., Sommerville, S., Snelling, B., Miller, T. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research
Inflammation and Severe Cerebral Venous Thrombosis
This study reviews the current literature regarding the involvement of inflammation in the pathophysiology and anti-inflammatory interventions of severe CVT, which would contribute to informing the pathophysiology mechanism and laying a foundation for exploring novel severe CVT therapeutic strategies.
Source: Frontiers in Neurology - July 22, 2022 Category: Neurology Source Type: research
Neuroprotective, Anti-inflammatory Effect of Furanochrome, Visnagin Against Middle Cerebral Ischemia-Induced Rat Model
In this study, the anti-ischemic effect of a furanochrome visnagin was assessed in in vivo rat model. Middle cerebral ischemic/reperfusion was induced in healthy male Sprague Dawley rats and treated with different concentrations of visnagin. The neuroprotective effect of visnagin against cerebral ischemia-induced rats was assessed by analyzing the neurological score, brain edema, infract volume, and Evans blue leakage. The anti-inflammatory property of visnagin was assessed by quantifying proinflammatory cytokines in serum and brain tissues of cerebral ischemia-induced rats. Prostaglandin E-2, COX-2, and NFκ-β were estim...
Source: Applied Biochemistry and Biotechnology - July 12, 2022 Category: Biochemistry Authors: Qiangyuan Tian Hua Yin Jisen Li Jinggong Jiang Binbin Ren Junhui Liu Source Type: research
Risk factors and predictors for venous thromboembolism in people with ischemic stroke: A systematic review
In conclusion, this systematic review informs on several potential risk factors and predictors for VTE in people with ischemic stroke. To improve risk stratification and guide development of risk prediction models, further confirmation is needed, as there were few high-quality studies on each factor.PMID:35815351 | DOI:10.1111/jth.15813
Source: Thrombosis and Haemostasis - July 11, 2022 Category: Hematology Authors: Birgitte G T øndel V ânia M Morelli John-Bjarne Hansen Sigrid K Braekkan Source Type: research
A lower admission level of interleukin-6 is associated with first-pass effect in ischemic stroke patients
Conclusion
A lower admission level of IL-6 is associated with FPE.
Source: Journal of NeuroInterventional Surgery - February 16, 2022 Category: Neurosurgery Authors: Mechtouff, L., Bochaton, T., Paccalet, A., Crola Da Silva, C., Buisson, M., Amaz, C., Derex, L., Ong, E., Berthezene, Y., Dufay, N., Ovize, M., Mewton, N., Cho, T.-H., Nighoghossian, N., Eker, O. F. Tags: Vascular neurology Source Type: research
The relationship between malignant tumors and ischemic stroke: I. Thrombosis development and shared risk factors
Orv Hetil. 2022 Jan 2;163(1):3-11. doi: 10.1556/650.2021.32328. Print 2022 Jan 2.ABSTRACTÖsszefoglaló. A malignus daganat és a stroke egy-egy betegnél gyakran kombinálódik, sokszor egyidejűleg diagnosztizálják, vagy rövid idő telik el a két kórkép felismerése között. Az együttes megjelenés hátterében elsősorban a hasonló tradicionális rizikófaktorok állhatnak: az idősebb életkor, a magas vérnyomás, a hyperlipidaemia, a cukorbetegség, az elhízás és a dohányzás. Az átfedő kockázati tényezőkön túl a daganat által okozott hiperkoaguláció artériás és vénás thrombosis kialakulá...
Source: Orvosi Hetilap - January 2, 2022 Category: General Medicine Authors: N óra Hajnóczky D ániel Bereczki Source Type: research
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Transfusion thresholds for guiding red blood cell transfusion
CONCLUSIONS: Transfusion at a restrictive haemoglobin concentration decreased the proportion of people exposed to RBC transfusion by 41% across a broad range of clinical contexts. Across all trials, no evidence suggests that a restrictive transfusion strategy impacted 30-day mortality, mortality at other time points, or morbidity (i.e. cardiac events, myocardial infarction, stroke, pneumonia, thromboembolism, infection) compared with a liberal transfusion strategy. Despite including 17 more randomised trials (and 8846 participants), data remain insufficient to inform the safety of transfusion policies in important and sele...
Source: Cochrane Database of Systematic Reviews - December 21, 2021 Category: General Medicine Authors: Jeffrey L Carson Simon J Stanworth Jane A Dennis Marialena Trivella Nareg Roubinian Dean A Fergusson Darrell Triulzi Carolyn Dor ée Paul C H ébert Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Role of MRI in Cerebral Venous Thrombosis
ConclusionDural venous occlusion can occur due to many factors as thrombosis, inflammatory conditions of the brain and tumors. Cerebral venous thrombosis (CVT) has long been a neglected entity because of complexities in diagnosis and non-specific clinical presentation. Conventional MRI and phase contrast MRV in conjugation with recent techniques such SWI& DWI were considered more accurate diagnostic tool, non invasive, non ionizing, with high resolution in evaluating patients with suspected cerebral venous occlusion or thrombosis. It is also considered very useful to demonstrate brain parenchymal affection, the age or ...
Source: QJM - October 1, 2021 Category: Internal Medicine Source Type: research
Development of Biomembrane-mimetic Nanoparticles for the Treatment of Ischemic Stroke
Yakugaku Zasshi. 2021;141(9):1071-1078. doi: 10.1248/yakushi.21-00114.ABSTRACTIncrease in vascular permeability of the blood-brain barrier (BBB) is a distinct pathology following ischemic stroke. In previous studies, we demonstrated that liposomal drug delivery system (DDS)-based delivery of neuroprotectants is useful for treating cerebral ischemia/reperfusion injury. Additionally, our previous studies reported that combination therapy with liposomal fasudil plus tissue plasminogen activator (t-PA), a thrombolytic agent, brings about decrease in the risk of t-PA-derived cerebral hemorrhage and prolong the therapeutic time ...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - September 2, 2021 Category: Drugs & Pharmacology Authors: Tatsuya Fukuta Source Type: research
